The European Commission (EC) will make a legally binding decision based on the EMA recommendation within 67 days. If granted by the EC, the marketing authorization is valid in all EU member states, as well as in the European Economic Area (EEA) countries Iceland, Lichtenstein and Norway.

Diflunisal has been granted Orphan Drug Designation (ODD) for the treatment of ATTR amyloidosis in the EU. An application for ODD in the US has been submitted. 

Related article

Financing Q&A: “Make sure your investors can add more than just money!”

Jonas Hansson is a Venture Partner at HealthCap, a European venture capital firm investing exclusively and globally in life sciences. What kind of companies are you and your colleagues focusing your investments on? And what stages?  “We invest in companies/assets in the precision medicine (right medicine for the right patient) space. We like to be […]


“We started Purpose Pharma with the objective to make diflunisal available for patients suffering from ATTR polyneuropathy, a severe and debilitating disease where, despite available therapies, significant unmet needs exist. If approved by the EC, Attrogy will be the first oral therapy approved for the treatment of both stage 1 and 2 ATTR polyneuropathy,” says Jonas Hansson, CEO of Purpose Pharma.